CREB1 and thyroid cancer: In contrast, we demonstrated that when the 8505C thyroid cancer cell line carrying BRAFV600E is treated with PLX4032, CREB activation is critically related to the drug’s antiproliferative effects via L-GILZ, which also exerts antiproliferative activity.